Table 2

Clinical, functional, disease activity and serological parameters of all (n=608) patients with PsA during 24 months-follow up

Total 608 patients with PsAT0T6T12T24P value
TJ (0–68), mean (SD)8.02 (6.82)3.64 (5.07)2.85 (4.81)1.60 (3.05)<0.01
SJ (0–66), mean (SD)2.25 (2.82)0.82 (1.53)0.61 (1.87)0.26 (0.69)0.03
LEI (0–6), mean (SD)1.62 (1.83)0.88 (1.45)0.39 (0.95)0.19 (0.62)0.04
Dactylitis (0–20) number digit, mean (SD)0.28 (1.27)0.07 (0.46)0.03 (0.27)0.01 (0.11)0.05
PASI (0–72), mean (SD)4.24 (7.38)1.69 (3.91)0.81 (2.21)0.88 (3.21)<0.01
ESR (0–25) (mm/hour), mean (SD)21.13 (17.08)15.71 (13.11)14.88 (13.59)14.94 (12.45)0.03
CRP (0–6) (mg/L), mean (SD)6.45 (9.82)4.13 (6.27)3.45 (5.01)3.49 (5.41)0.03
DAPSA (0–164), mean (SD)25.29 (11.14)14.07 (9.69)12.12 (9.97)7.69 (4.51)<0.01
ASDAS (0–6), mean (SD)3.26 (0.88)2.11 (1.03)1.82 (1.02)1.60 (0.69)0.02
HAQ-S (0–8), mean (SD)1.28 (8.23)0.89 (0.69)0.69 (0.71)0.53 (0.64)0.05
VAS-pain (0–10), mean (SD)6.70 (1.67)4.30 (2.28)3.28 (2.51)2.52 (2.32)0.02
VAS-gh (0–10), mean (SD)6.71 (4.93)4.25 (2.24)3.10 (2.44)2.41 (2.31)0.02
BASDAI (0–10), mean (SD)5.22 (2.17)3.52 (2.53)3.35 (2.16)2.60 (1.61)0.03
BASFI (0–10), mean (SD)5.17 (2.14)3.72 (2.02)2.82 (1.87)2.48 (1.34)0.03
  • Data are expressed as mean (SD). Values were computed by means of a χ2 test (for proportion) or Wilcoxon’s test (for continuous data), p≤0.05 T24 vs T0.

  • ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; CRP, C reactive protein; DAPSA, Disease Activity Index for Psoriatic Arthritis; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire modified for spondyloarthritis; LEI, Leeds Enthesitis Index; PASI, Psoriasis Area Severity Index; SJ, swollen joint; TJ, tender joint; VAS-gh, Visual Analogue Scale global health; VAS-pain, Visual Analogue Scale pain.